PARIS (Reuters) – Sanofi raised its 2021 outlook after its vaccines and star eczema treatment Dupixent helped it post better-than-expected second-quarter results on Thursday.
The French drugmaker said it was now targeting earnings per share to grow around 12% at constant exchange rates this year. It had previously been expecting a “high single digit” rise in earnings.
(Reporting by Matthias Blamont; Editing by Jacqueline Wong)
